Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
May 10, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., May 10, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights
May 03, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., May 03, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces Review of Strategic Alternatives
April 18, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., April 18, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
April 10, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Reports 2017 Financial Results and Recent Highlights
March 19, 2018 08:00 ET
|
Fibrocell Science Inc
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on...
Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
March 12, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
March 06, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Present at 20th Annual BIO CEO & Investor Conference
February 06, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
February 05, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
January 30, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...